Picture [iito] Männer Ballett 650x80px
Document › Details

Abzena Ltd.. (7/28/20). "Press Release: Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners". Cambridge, Bristol, PA & San Diego, CA.

Organisations Organisation Abzena Ltd.
  Today Abzena plc (AIM: ABZA)
  Group Abzena (Group)
  Organisation 2 Biospring Partners (US)
Products Product reagents (bio/biochemical)
  Product 2 private equity
Index terms Index term Abzena–Biospring Partners: investment, 202007 investment $10m by Lifespring Partners
  Index term 2 Abzena–Welsh Carson Anderson & Stowe: investment, 201808– recommended cash offer 16p/share valueing Abzena at £34.4m by WCAS XII-Astra LP
Persons Person Goldman, Jonathan (Aptuit 201604 CEO)
  Person 2 Dipp, Michelle (Biospring Partners 2020– Co-Founder)

Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.

The new capital will allow Abzena to accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in the first half of 2020. “The investment by Biospring Partners is further validation that the Abzena integrated model is the future of biologics drug development and manufacturing,” said Jonathan Goldman MD, CEO of Abzena. “Michelle Dipp and Jennifer Lum founded Biospring based upon their deep expertise in life sciences and technology industries. Abzena will benefit from Biospring’s access to a broad network of potential customers and their expertise in building and operating growth stage companies. Access to new customer partners and operating expertise is essential for the continuing growth of the company.”

“It is an exciting time to join Abzena’s board. Abzena is uniquely positioned to take advantage of the global market opportunity for large molecules as the biopharmaceutical industry increasingly outsources development and manufacturing,” said Dr. Dipp. “Abzena is the industry leader for the comprehensive and integrated development of biologics and ADCs.”

“We are thrilled to have Dr. Dipp join the board of Abzena, one of our portfolio companies,” said Nick O’Leary of Welsh, Carson, Anderson and Stowe. “Dr. Dipp’s expertise in life sciences and the additional capital Biospring has invested will allow Abzena to continue its global growth and market reach.”

About Abzena

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see

About Biospring Partners

Biospring Partners invests in growth stage life sciences technology companies. Founded in 2020, by Michelle Dipp, MD PhD and Jennifer Lum, Biospring is focused on companies using technology to drive innovation and efficiency across the life sciences sector. Biospring is uniquely positioned to partner with life sciences technology companies that have the potential to fundamentally change how we research, diagnose and treat disease. For more information, please see

About Welsh, Carson, Anderson and Stowe

WCAS is a leading U.S. private equity firm focused on two target industries: healthcare and technology. Since its founding in 1979, the firm’s strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. WCAS has deep experience in acquiring founder-led businesses and corporate carve-outs. The firm has raised and managed funds totaling over $27 billion of committed capital. For more information, please visit

Record changed: 2020-09-04


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Abzena (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top